A phase I study of the safety, pharmacokinetic and pharmacodynamic properties of intravenously administered APG-1252 in patients with small cell lung cancer (SCLC) or other solid tumors

Trial Profile

A phase I study of the safety, pharmacokinetic and pharmacodynamic properties of intravenously administered APG-1252 in patients with small cell lung cancer (SCLC) or other solid tumors

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 15 Jan 2018

At a glance

  • Drugs APG 1252 (Primary)
  • Indications Small cell lung cancer; Solid tumours
  • Focus Adverse reactions
  • Acronyms APG-1252-AU-001
  • Sponsors Jiangsu Ascentage Pharma
  • Most Recent Events

    • 12 Jan 2018 Planned End Date changed from 28 Feb 2019 to 29 Feb 2020.
    • 12 Jan 2018 Planned initiation date changed from 1 Dec 2016 to 22 Jan 2018.
    • 24 Nov 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top